TB Drug Accelerator Program
Aiming to speed up the discovery and development of novel compounds against tuberculosis (TB)....
AbbVie, AstraZeneca, Bayer AG, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, MSDHow the innovative biopharmaceutical industry and our partners are achieving the Sustainable Development Goals (SDGs)
Explore our collaborationsOver 35 IFPMA members are working with partners from academia, development organizations, NGOs, foundations and other business sectors.
Learn MoreWith over 250 collaborations, Global Health Progress details the scope, scale, and breadth of our collaborations working to strengthen health systems and expand access to quality healthcare.
Learn MoreFounded on patients need, we are strengthening health systems by developing and producing medicines to meet these needs and increasing the availability, accessibility and affordability of health services.
Learn MoreThe private sector has a key role to play in addressing the global challenges we face in health, wellbeing and prosperity. Our efforts help to address these challenges and support SDGs.
Learn more about the SDGsExplore the full depth and diversity of our collaborations
Aiming to speed up the discovery and development of novel compounds against tuberculosis (TB)....
AbbVie, AstraZeneca, Bayer AG, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, MSDOn 30 January 2012, pharmaceutical companies, donors, endemic countries and non-government organisations came...
AbbVie, Bayer AG, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Johnson & Johnson, Merck, MSD, Novartis, Pfizer Inc, SanofiTackling the growing burden of non-communicable diseases in low and middle-income countries and supporting...
Access Accelerated, Almirall, Astellas Pharma Inc, Bayer AG, Bristol Myers Squibb, Celgene, Chiesi Farmaceutici, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, F. Hoffmann – La Roche Ltd., International Federation of Pharmaceutical Manufacturers & Associations, Johnson & Johnson, Menarini Group, Merck, MSD, Novartis, Pfizer Inc, Sanofi, Servier, Shionogi & Co., Ltd., Sumitomo Pharma, Takeda Pharmaceutical Company Limited, UCBOver the past decade strong progress has been made on a number of diseases but there is still much to be done to step up the fight and ensure universal health for all.
Access Accelerated unites more than 20 innovative biopharmaceutical companies and partners to tackle the non-communicable diseases (NCDs) burden in low- and middle-income countries (LMICs). Access Accelerated has developed the Access Accelerated Open Platform, a first of-its-kind resource to share knowledge and catalyze action around advancing NCD prevention, treatment and care.
Explore the Access Accelerated Open Platform50 Years of Global Health Progress traces global health progress over the half century and the pioneering collaborative role the innovative biopharmaceutical industry has played not only to deliver prevention and treatment, but to strengthen health systems around the world.